mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.
Company profile
Ticker
MBIO
Exchange
Website
CEO
Manuel Litchman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MBIO stock data
Latest filings (excl ownership)
8-K
Cost Associated with Exit or Disposal Activities
12 Apr 24
S-1/A
IPO registration (amended)
2 Apr 24
8-K
Other Events
29 Mar 24
S-1
IPO registration
15 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 24
8-K
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Other Events
14 Feb 24
8-K
Departure of Directors or Certain Officers
25 Jan 24
8-K
Other Events
4 Jan 24
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
3
JAMES B MURPHY
12 Feb 24
4
Change in insider ownership
3 Jan 24
3
Peter Carney
19 Dec 23
4
MICHAEL J ZELEFSKY
7 Jul 23
4
Adam J. Chill
7 Jul 23
4
LINDSAY A MD ROSENWALD
7 Jul 23
4
MICHAEL S WEISS
7 Jul 23
4
Neil Herskowitz
7 Jul 23
4
Manuel MD Litchman
7 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.31 mm | 10.31 mm | 10.31 mm | 10.31 mm | 10.31 mm | 10.31 mm |
Cash burn (monthly) | 1.94 mm | 6.84 mm | 3.44 mm | 5.00 mm | 4.01 mm | 4.79 mm |
Cash used (since last report) | 13.23 mm | 46.59 mm | 23.41 mm | 34.04 mm | 27.31 mm | 32.66 mm |
Cash remaining | -2.91 mm | -36.28 mm | -13.10 mm | -23.73 mm | -17.00 mm | -22.35 mm |
Runway (months of cash) | -1.5 | -5.3 | -3.8 | -4.8 | -4.2 | -4.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 29 |
Opened positions | 7 |
Closed positions | 29 |
Increased positions | 0 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 3.65 bn |
Total shares | 23.52 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FBIO Fortress Biotech | 22.88 mm | $12.77 mm |
Vanguard | 177.58 k | $1.10 bn |
BLK Blackrock | 101.57 k | $630.74 mm |
Koss-Olinger Consulting | 100.00 k | $621.00 mm |
Laurion Capital Management | 51.01 k | $316.75 mm |
Geode Capital Management | 49.76 k | $309.02 mm |
Renaissance Technologies | 44.39 k | $276.00 k |
Dimensional Fund Advisors | 26.81 k | $166.50 mm |
HighTower Advisors | 19.53 k | $122.00 mm |
STT State Street | 16.02 k | $99.47 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 419,092 | 0.00 | 1,927,800 |
6 Jan 23 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 2,807,008 | 0.00 | 22,630,620 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
18 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
Mustang Bio Expands CAR T-Cell Therapy Platform Expansion Into Autoimmune Diseases
28 Mar 24
Mustang Bio Reports FY23 EPS Of $(6.00) Vs $(10.09) YoY And Recent Corporate Highlights
11 Mar 24
Press releases
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
28 Mar 24
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
7 Mar 24
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
7 Mar 24